Our Vision

Patients with end-stage heart failure continue to face significant challenges. While heart transplantation is the only definitive cure, there is a growing demand for more effective and accessible therapies.

Since 2017, at the Shudo Laboratory, we focus on developing innovative tissue engineering strategies that integrate bio-engineering, bio-mechanics, and bio-statistics.

Despite improvements in heart transplantation outcomes, ischemic reperfusion injury remains a leading cause of primary graft failure, early dysfunction, delayed recovery, and increased one-year mortality.

Since 2023, to address this, we have developed novel bio-cellular strategies to mitigate reperfusion injury.

We utilize both small animal models, such as mice and rats, and large animal models, like pigs, in our translational research to develop treatments that improve patient outcomes.

Through our interdisciplinary research—from molecular biology to tissue engineering and surgical applications—we aim to enhance the quality of life for heart failure patients.

We also welcome collaborative efforts with other researchers and institutions. Our lab is open to joint research projects that can drive forward groundbreaking discoveries in cardiac transplantation and heart failure treatments.